{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:38:46Z","timestamp":1791391126997,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The study was funded by Zambon S.p.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40263-022-00958-6","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T02:42:39Z","timestamp":1667875359000},"page":"1217-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson\u2019s Disease with Motor Fluctuations"],"prefix":"10.1007","volume":"36","author":[{"given":"Qianqian","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuneng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshuang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the XINDI Study Investigators Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuncheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuneng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houzhen","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueshuang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"958_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"958_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10072-010-0461-8","volume":"32","author":"YY Tian","year":"2011","unstructured":"Tian YY, Tang CJ, Wu J, Zhou JS. Parkinson\u2019s disease in China. Neurol Sci. 2011;32:23\u201330.","journal-title":"Neurol Sci"},{"key":"958_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2165\/00002512-200623090-00001","volume":"23","author":"CH Dowding","year":"2006","unstructured":"Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson\u2019s disease. Drugs Aging. 2006;23:693\u2013721.","journal-title":"Drugs Aging"},{"key":"958_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF03033378","volume":"5","author":"TN Chase","year":"2003","unstructured":"Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res. 2003;5:139\u201346.","journal-title":"Neurotox Res"},{"key":"958_CR5","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","volume":"73","author":"SH Fox","year":"2013","unstructured":"Fox SH. Non-dopaminergic treatments for motor control in Parkinson\u2019s disease. Drugs. 2013;73:1405\u201315.","journal-title":"Drugs"},{"key":"958_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA. Levodopa: past, present and future. Eur Neurol. 2009;62:1\u20138.","journal-title":"Eur Neurol"},{"key":"958_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, M\u00fcnter MD. Frequency of levodopa related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448\u201358.","journal-title":"Mov Disord"},{"key":"958_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40263-015-0247-x","volume":"29","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Curtiz MM. Impact on quality of life in patients with Parkinson\u2019s disease. CNS Drugs. 2015;29:397\u2013413.","journal-title":"CNS Drugs"},{"key":"958_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40035-016-0059-z","volume":"5","author":"S Chen","year":"2016","unstructured":"Chen S, Chan P, Sun S, Chen H, Zhang B, Le W, et al. Parkinson\u2019s disease and movement disorder society consensus on therapeutic management of Parkinson\u2019s disease. Transl Neurodegener. 2016;5:12. https:\/\/doi.org\/10.1186\/s40035-016-0059-z.","journal-title":"Transl Neurodegener."},{"key":"958_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40262-016-0449-5","volume":"56","author":"T M\u00fcller","year":"2017","unstructured":"M\u00fcller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56:251\u201361.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"958_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord. 2014;29(2):229\u201337.","journal-title":"Mov Disord"},{"key":"958_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson\u2019s disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:216\u201324.","journal-title":"JAMA Neurol"},{"key":"958_CR13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29:1273\u201380.","journal-title":"Mov Disord"},{"key":"958_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. Efficacy and safety of safinamide as an add-on therapy to L-dopa for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study. Parkinsonism Relat Disord. 2020;75:17\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"958_CR15","volume-title":"Parkinson\u2019s disease: national clinical guideline for diagnosis and management in primary and secondary care","author":"National Collaborating Centre for Chronic Conditions","year":"2006","unstructured":"National Collaborating Centre for Chronic Conditions. Parkinson\u2019s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006."},{"issue":"5","key":"958_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"M Hoehn","year":"1967","unstructured":"Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427\u201342.","journal-title":"Neurology"},{"issue":"2","key":"958_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O\u2019Brien CF, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol"},{"key":"#cr-split#-958_CR18.1","doi-asserted-by":"crossref","unstructured":"E G Brown, L Wood, S Wood. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999","DOI":"10.2165\/00002018-199920020-00002"},{"key":"#cr-split#-958_CR18.2","unstructured":"Feb;20(2):109-17. (Updated on 2020 Sep 24)"},{"issue":"10","key":"958_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"Parkinson Study Group","year":"1989","unstructured":"Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinsons disease. Arch Neurol. 1989;46(10):1052\u201360.","journal-title":"Arch Neurol"},{"key":"958_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.26731","volume":"31","author":"R Martinez-Fernandez","year":"2016","unstructured":"Martinez-Fernandez R, Schmitt E, Martinez-Martin P, Krack P. The hidden sister of motor fluctuations in Parkinson\u2019s disease: a review on nonmotor fluctuations. Mov Disord. 2016;31:1080\u201394.","journal-title":"Mov Disord"},{"key":"958_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/2047-9158-3-26","volume":"3","author":"W Chen","year":"2014","unstructured":"Chen W, Xiao Q, Shao M, Feng T, Liu WG, Luo XG, et al. Prevalence of wearing-off and dyskinesia among the patients with Parkinson\u2019s disease on levodopa therapy: a multi-center registry survey in mainland China. Transl Neurodegener. 2014;3:26.","journal-title":"Transl Neurodegener."},{"key":"958_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20:224\u201330.","journal-title":"Mov Disord"},{"key":"958_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1353-8020(02)00097-4","volume":"9","author":"T Ker\u00e4nen","year":"2003","unstructured":"Ker\u00e4nen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Rel Disord. 2003;9:163\u20138.","journal-title":"Parkinsonism Rel Disord."},{"issue":"5","key":"958_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/mds.23638","volume":"26","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Auinger P. Determination of minimal clinically important change in early and advanced Parkinson\u2019s disease. Mov Disord. 2011;26(5):813\u20138.","journal-title":"Mov Disord"},{"key":"958_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-018-0119-7","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Shao M, Chen S, Liu WG, Luo C, Peng R, et al. Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations; a randomized, double-blind study in China. Transl Neurodegener. 2018;7:14.","journal-title":"Transl Neurodegener."},{"key":"958_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF02740748","volume":"12","author":"F Blandini","year":"1996","unstructured":"Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson\u2019s disease. Mol Neurobiol. 1996;12:73\u201394.","journal-title":"Mol Neurobiol"},{"key":"958_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","volume":"90","author":"J Pagonabarraga","year":"2021","unstructured":"Pagonabarraga J, Tinazzi M, Caccia C, Jost WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: clinical cases and a review of the literature. J Clin Neurosci. 2021;90:178\u201383.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"958_CR28","first-page":"64","volume":"67","author":"LM Shulman","year":"2021","unstructured":"Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the Unified Parkinson\u2019s Disease Rating Scale. Arch Neurol. 2021;67(1):64\u201370.","journal-title":"Arch Neurol"},{"key":"958_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/0272989X05276863","volume":"25","author":"B Barret","year":"2005","unstructured":"Barret B, Brown D, Mundt M, Brown R. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making. 2005;25:250\u201361.","journal-title":"Med Decis Making"},{"issue":"1","key":"958_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JPD-191765","volume":"10","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Jost WH, Bonizzoni E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s disease patients. J Parkinsons Dis. 2020;10(1):89\u201397.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"958_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3233\/JPD-202224","volume":"11","author":"G Abbruzzese","year":"2021","unstructured":"Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, K\u00e4gi G, Raw J, et al. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial. J Parkinsons Dis. 2021;11(1):187\u201398.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"958_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, M\u00fcller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C. Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease. J Parkinsons Dis. 2017;7(4):629\u201334.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"958_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/brainsci11020232","volume":"11","author":"E Pena","year":"2021","unstructured":"Pena E, Borru\u00e9 C, Mata M, Martinez-Castrillo JC, Alonso-Canovas A, Chico JL, et al. Impact of SAfinamide on Depressive Symptoms in Parkinson\u2019s Disease Patients (SADness-PD Study): a multicenter retrospective study. Brain Sci. 2021;11(2):232.","journal-title":"Brain Sci"},{"issue":"3","key":"958_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3233\/JPD-150569","volume":"5","author":"C Cattaneo","year":"2015","unstructured":"Cattaneo C, La Ferla R, Bonizzoni E, Sardina M. Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson\u2019s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5(3):475\u201381.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"958_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17925\/ENR.2015.10.01.15","volume":"10","author":"J Schnitker","year":"2015","unstructured":"Schnitker J, M\u00fcller T. Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson\u2019s disease. Eur Neurol Rev. 2015;10(1):15\u201322.","journal-title":"Eur Neurol Rev."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00958-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T05:32:53Z","timestamp":1668231173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00958-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00958-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"12 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study and its open access publication was funded by Zambon S.p.A. or similar","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study and its open access publication was funded by Zambon S.p.A. Carlo Cattaneo is an employee at Zambon S.p.A. Qianqian Wei, Yuyan Tan, Pingyi Xu, Enxiang Tao, Zuneng Lu, Xiaoping Pan, Baojun Wang, Chunfeng Liu, Xueshuang Dong, Yuling Tian, and Xin Sun have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by all appropriate independent ethics committees and by the Chinese regulatory authority.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from Zambon S.p.A but restrictions apply to the availability of these data, which were used under license for the current study, and thus are not publicly available. However, data are available from the authors upon reasonable request and with permission of Zambon S.p.A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to writing and reviewing the paper and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}